Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes (Q38083047)

28 August 2017

Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes (English)

1 reference

28 August 2017

1 reference

3

1 reference

28 August 2017

Michael Horowitz

1

1 reference

28 August 2017

Christopher K Rayner

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

13 February 2013

1 reference

28 August 2017

1 reference

28 August 2017

30

1 reference

28 August 2017

2

1 reference

28 August 2017

81-101

1 reference

https://scigraph.springernature.com/pub.10.1007/s12325-013-0009-4

28 August 2017

0 references

cites work

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Regulation of glucose transporters and hexose uptake in 3T3-L1 adipocytes: glucagon-like peptide-1 and insulin interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

In vivo expression of HGF/NK1 and GLP-1 From dsAAV vectors enhances pancreatic ß-cell proliferation and improves pathology in the db/db mouse model of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Glucagon-like peptide-1 protects beta-cells against apoptosis by increasing the activity of an IGF-2/IGF-1 receptor autocrine loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

GLP-1 based therapies: differential effects on fasting and postprandial glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Disordered gastric emptying: mechanical basis, assessment and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Impaired secretion of total glucagon-like peptide-1 in people with impaired fasting glucose combined impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

A population association study of four candidate genes (hexokinase II, glucagon-like peptide-1 receptor, fatty acid binding protein-2, and apolipoprotein C-II) with type 2 diabetes and impaired glucose tolerance in Japanese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0009-4

10.1007/S12325-013-0009-4

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference